Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Matthias Wirth

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8340-0872; OpenAlex author ID A5009251187. Sources: OpenAlex.

Their work

Papers
27 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
95
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 3 papers · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: 3 papers · 2021: 1 paper · 2022: 6 papers · 2023: none · 2024: 3 papers · 2025: 1 paper · 2026: 4 papers

Papers 27

  1. The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/mco2.70794↗
  2. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Co-author DOI 10.1038/s41591-026-04234-8↗
  3. Targeting Mutual Dependence of Phosphatidylinositol-3-Kinase α/δ and Small Ubiquitin-Like Modifier Signaling in Pancreatic Cancer. Last author DOI 10.1053/j.gastro.2025.08.018↗
  4. Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam. Co-author DOI 10.1158/2767-9764.crc-25-0670↗
  5. KRAS G 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. Co-author DOI 10.1002/1878-0261.13725↗
  6. A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction. Co-author DOI 10.1002/advs.202307695↗
  7. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Co-author DOI 10.1038/s41591-024-03054-y↗
  8. A Hypoxia-Epigenetics Axis Drives EMT in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-23-3578↗
  9. Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition. Co-author DOI 10.1002/cac2.12280↗
  10. AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer. Co-author DOI 10.1007/s00018-022-04638-y↗
  11. Targeting the translational machinery to overcome apoptosis resistance in pancreatic cancer. Co-author DOI 10.1016/j.tranon.2022.101343↗
  12. NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer. Last author DOI 10.1073/pnas.2105691119↗
  13. HDAC2 Facilitates Pancreatic Cancer Metastasis. Co-author DOI 10.1158/0008-5472.can-20-3209↗
  14. Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. Co-author DOI 10.1172/jci.insight.151353↗
  15. Rationale for MYC imaging and targeting in pancreatic cancer. First author DOI 10.1186/s13550-021-00843-1↗
  16. Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. Last author DOI 10.1002/1878-0261.12835↗
  17. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. Co-author DOI 10.1136/gutjnl-2018-317856↗
  18. Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. Co-author DOI 10.1172/jci.insight.137809↗
  19. Regulation of Epithelial Plasticity Determines Metastatic Organotropism in Pancreatic Cancer. Co-author DOI 10.1016/j.devcel.2018.05.025↗
  20. MTOR inhibitor-based combination therapies for pancreatic cancer. Co-author DOI 10.1038/bjc.2017.421↗
  21. HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer. Co-author DOI 10.1038/onc.2016.344↗
  22. MYC: A Stratification Marker for Pancreatic Cancer Therapy. Co-author DOI 10.1016/j.trecan.2015.12.002↗
  23. Concepts to Target MYC in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-16-0050↗
  24. Membranous CD24 drives the epithelial phenotype of pancreatic cancer. Co-author DOI 10.18632/oncotarget.9402↗
  25. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/nm.3952↗
  26. Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death. Co-author DOI 10.1002/ijc.27916↗
  27. A simple and cost-effective method to transfect small interfering RNAs into pancreatic cancer cell lines using polyethylenimine. Co-author DOI 10.1097/mpa.0b013e3181f7e41c↗

Closest collaborators

The 25 strongest of 95 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Günter Schneider · 23 shared papers, 2011–2026 · strength 2.91
  2. Dieter Saur · 18 shared papers, 2011–2026 · strength 2.07
  3. Maximilian Reichert · 17 shared papers, 2013–2026 · strength 1.82
  4. Elisabeth Heßmann · 9 shared papers, 2015–2026 · strength 1.41
  5. Christian Schneeweis · 10 shared papers, 2018–2026 · strength 1.31
  6. Lukas Krauß · 8 shared papers, 2022–2026 · strength 1.19
  7. Carolin Schneider · 8 shared papers, 2022–2026 · strength 1.19
  8. Roland Rad · 11 shared papers, 2017–2026 · strength 1.17
  9. Roland Michael Schmid · 12 shared papers, 2011–2026 · strength 1.09
  10. Volker Ellenrieder · 7 shared papers, 2015–2026 · strength 1.08
  11. Oliver Holger Krämer · 10 shared papers, 2013–2026 · strength 1.01
  12. Michael B. Ghadimi · 5 shared papers, 2024–2026 · strength 0.92
  13. Ulrich Bernd Keller · 6 shared papers, 2020–2026 · strength 0.88
  14. Felix Orben · 7 shared papers, 2020–2026 · strength 0.84
  15. Marian Grade · 5 shared papers, 2022–2026 · strength 0.83
  16. Zonera Hassan · 8 shared papers, 2017–2022 · strength 0.77
  17. Constanza Tapia Contreras · 4 shared papers, 2024–2026 · strength 0.71
  18. Hazal Köse · 3 shared papers, 2022–2026 · strength 0.52
  19. Iréne Esposito · 4 shared papers, 2015–2026 · strength 0.49
  20. Irina Heid · 5 shared papers, 2015–2026 · strength 0.49
  21. Jens Thomas Siveke · 5 shared papers, 2015–2026 · strength 0.49
  22. Rickmer Braren · 5 shared papers, 2015–2026 · strength 0.49
  23. Alexander Herner · 4 shared papers, 2015–2026 · strength 0.44
  24. Bence Sipos · 4 shared papers, 2015–2026 · strength 0.42
  25. Lena‐Christin Conradi · 2 shared papers, 2025–2026 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.